Intellia Therapeutics, Inc.
NTLA
$12.31
$0.110.90%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.04% | 16.92% | 33.52% | 14.99% | -13.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.04% | 16.92% | 33.52% | 14.99% | -13.37% |
| Cost of Revenue | -24.86% | -18.90% | -14.61% | -8.55% | -7.14% |
| Gross Profit | 33.42% | 24.60% | 19.96% | 11.33% | 6.31% |
| SG&A Expenses | 2.38% | -2.28% | 12.19% | 23.72% | 40.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.02% | -14.10% | -7.67% | -0.90% | 2.93% |
| Operating Income | 22.24% | 17.46% | 10.97% | 2.29% | -4.59% |
| Income Before Tax | 24.97% | 20.49% | 14.64% | 5.62% | -8.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.97% | 20.49% | 14.64% | 5.62% | -8.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.97% | 20.49% | 14.64% | 5.62% | -8.32% |
| EBIT | 22.24% | 17.46% | 10.97% | 2.29% | -4.59% |
| EBITDA | 22.52% | 17.70% | 11.14% | 2.39% | -4.51% |
| EPS Basic | 32.42% | 27.11% | 21.66% | 14.42% | 2.57% |
| Normalized Basic EPS | 28.32% | 22.30% | 17.16% | 11.24% | 6.89% |
| EPS Diluted | 32.42% | 27.11% | 21.66% | 14.42% | 2.57% |
| Normalized Diluted EPS | 28.32% | 22.30% | 17.16% | 11.24% | 6.89% |
| Average Basic Shares Outstanding | 11.16% | 9.61% | 9.20% | 10.36% | 11.17% |
| Average Diluted Shares Outstanding | 11.16% | 9.61% | 9.20% | 10.36% | 11.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |